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Background: Alkaline sphingomyelinase (NPP7) is an ecto-enzyme expressed in intestinal mucosa, which hydrolyses
sphingomyelin (SM) to ceramide and inactivates platelet activating factor. It is also expressed in human liver and
released in the bile. The enzyme may have anti-tumour and anti-inflammatory effects in colon and its levels are
decreased in patients with colon cancer and ulcerative colitis. Active NPP7 is translated from a transcript of 1.4 kb,
whereas an inactive form from a 1.2 kb mRNA was found in colon and liver cancer cell lines. While the roles of
NPP7 in colon cancer have been intensively studied, less is known about the function and implications of NPP7 in
the bile. The present study examines the changes of NPP7 in bile of patients with various hepatobiliary diseases.
Methods: Bile samples were obtained at endoscopic retrograde cholangiopancreatography (ERCP) in 59 patients
with gallstone, other benign disease, tumour, and primary sclerosing cholangitis (PSC). The NPP7 activity was
determined. The appearance of the 1.4 and 1.2 kb products in the bile was examined by Western blot. The results
were correlated to the diseases and also plasma bilirubin and alkaline phosphatase.
Results: NPP7 activity in the tumour group was significantly lower than in the gallstone group (p < 0.05). The
activity in the tumour plus PSC group was also lower than in gallstone plus other benign disease group (p < 0.05).
Within the tumour group NPP7 activity was lowest in cholangiocarcinoma patients, being only 19% of that in
gallstone patients. Bilirubin correlated inversely to NPP7 and was higher in the tumour than in the gallstone group.
Western blot identified both the 1.4 kb and the 1.2 kb products in most bile samples. The density ratio for the
1.4/1.2 kb products correlated to NPP7 activity significantly. Two patients (one PSC and one cholangiocarcinoma)
lacking NPP7 activity had only the 1.2 kb form in bile.
Conclusion: NPP7 activity and the ratio of 1.4/1.2 kb products in bile are significantly decreased in malignancy,
particularly in cholangiocarcinoma. The implications of the finding in diagnosis of cholangiocarcinoma and 1.2 kb
product in hepatobiliary diseases require further investigation.
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Table 1 Age, sex and diseases of patients in groups
Group Gallstone Tumour PSC Others Total
Number 29 13 10 7 59
Female 19 7 6 3 35
Male 10 6 4 4 24
Age range 33–85 60–79 20–82 53–83 20–85
Median age 67 66 48 67 66
Mean age 68.5 66.0 50.2 68.4 65.2
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Alkaline sphingomyelinase is an intestinal brush border
enzyme highly expressed in jejunum and ileum [1,2] and
released into the lumen by bile salts and trypsin [3,4]. It is
resistant to pancreatic and faecal proteases [3] and high
activity can be detected in the faeces [5]. Purification and
cloning showed that the enzyme is a novel member of nu-
cleotide pyrophosphatase phosphodiesterase (NPP) family
and is now called NPP7 [6,7]. NPP7 cleaves phospho-
choline moiety from both exogenous and endogenous
sphingomyelin (SM) in the gut and turns SM to ceramide.
Ceramide is a lipid messenger that inhibits cell prolife-
ration and induces apoptosis and may counteract cancer
development [8]. Via its phospholipase C activity NPP7
also hydrolyses and inactivates platelet activating factor
(PAF) [9], an important molecule with proinflammatory
properties [10]. NPP7 has thus important roles in gene-
ration of sphingolipid signals, regulation of PAF functions
and in the absorption and reutilization of choline in the
gut [11]. Our recent study in NPP7 -/- mice has con-
firmed the key role of the enzyme in SM digestion and
ceramide generation in the intestinal tract [12].
NPP7 activity was also identified in human bile but
not in bile of other species including rat, mice, pig,
rabbit and baboon [1,13,14]. Since in humans the acti-
vity was not detected in the mucosa of gallbladder, bile
NPP7 was indicated to be derived from liver. This was
confirmed later by identification of NPP7 mRNA in
HepG2 cells [15]. Physiologically, bile NPP7 may con-
tribute to a more efficient digestion of SM in humans,
since in patients with ileostomy, most of fed SM is
hydrolysed and absorbed [16], whereas in rodents, SM
digestion is relatively slow, extended and incomplete
[17]. We previously showed that dietary SM inhibited
cholesterol absorption and this inhibition was also more
obvious in rodents than in humans [16,18].
Several pieces of evidence suggest anti-inflammatory
and anti-tumour roles of NPP7 [11]. NPP7 activities de-
crease in patients with colon cancer [19], longstanding
colitis [20] and familial adenomatous polyposis [21]. Incu-
bation of the enzyme with colon carcinoma HT 29 cells
inhibits cell proliferation [22]. In dextran sulphate induced
experimental colitis in rats, rectal installation of the en-
zyme alleviates colitis [23]. Hypotheses behind these
effects have been linked to the generation of ceramide and
to the inactivation of PAF [11,24]. The impact of NPP7 in
liver cancer is a field that has not been extensively ex-
plored, although preliminary assay in human liver biopsies
showed that the NPP7 level tended to be lowered in liver
diseases predisposing to liver tumours [15].
Due to the alternative splicing, two isoforms of NPP7
have been identified in both colon cancer HT29 and liver
cancer HepG2 cell lines [25,15]. The active full length
NPP7 is a protein translated from 1.4 kb transcriptconsisting of 5 exons. The aberrant splicing form lacks
exon 4 and the protein translated from it has no activity
against SM [25]. Considering the intensive studies on
NPP7 in the intestine, relatively little is known about the
enzyme expressed in the liver. Liver is an important organ
in terms of synthesis and secretion of SM [26] and pro-
bably PAF [27,28], two major substrates of NPP7. We
therefore asked how the NPP7 activity in bile varies with
different hepatobiliary diseases and whether the changed
NPP7 activity or appearance of the 1.2 kb form in bile
could be linked to these diseases, and thus be a potential
disease marker. In the present study, we analysed NPP7
activity and the occurrence of two isoforms in bile from
59 patients undergoing diagnostic and/or therapeutic
endoscopic retrograde cholangiopancreatography (ERCP).
Methods
Patients
The study was approved by the Regional Ethics Committee
of Lund University (Nr 443/2008) and was conducted in
agreement with the Declaration of Helsinki from 1975, as
revised in 1983. Patients undergoing ERCP on clinical
indications were asked about permission to take a bile
sample for the study during the examination. Approved
written consent after both oral and written information
was obtained from all 59 patients. Patient characteristics
are given in Table 1. Major patient groups were those with
gallstones, tumours and primary sclerosing cholangitis
(PSC). Primary outcome of the study was to test the
hypothesis that patients with tumours or PSC have lower
NPP7 activity and/or more frequent appearance of the
1.2 kb form than those with gallstones or other benign
disease. Bile samples were collected during standard ERCP
procedures. Briefly, the papilla was cannulated with a
sphincterotome. A guide-wire was then introduced. When
it was positioned in the bile duct, the sphincterotome was
introduced further and bile was aspirated with a 10 ml
syringe. The bile samples were immediately stored on ice
and sent to the laboratory for sample preparation as
described below.
Sample preparation
The bile samples were centrifuged at 14000 rpm for
10 min at 4°C to remove the undissolved materials. A
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bile for NPP7 activity assay and protein determination.
The rest of the samples were subjected to protein pre-
cipitation by ammonium sulphate which was added step
by step up to 40% saturation with stirring. The samples
were kept stirring at 4°C for 1 h followed by centrifuga-
tion at 14000 rpm for 10 min. The precipitated protein
pellet was dissolved in PBS buffer and stored at -20°C
for Western blot analysis.
NPP7 and bile alkaline phosphatase activity assays
The activity of NPP7 in the bile against SM was deter-
mined as described previously, using 14C- choline la-
belled SM as substrate [29]. Briefly, 5 μl of the original
bile was incubated in 95 μl 50 mM Tris–HCl buffer con-
taining 0.15 M NaCl, 80 pmole 14C-SM, 4 μg unlabelled
SM, 10 mM taurocholate, 2 mM EDTA, pH 9.0 at 37°C
for 30 min. After phase partitioning, an aliquot of the
upper phase containing the cleaved 14C-phosphocholine
was taken for liquid scintillation counting. The activity
of NPP7 was expressed as the formation of phosphocho-
line in 1 h by per ml of bile and by per mg protein in
the bile samples. Alkaline phosphatase (ALP) activity in
the bile was determined using β-nitrophenylphosphate
as substrate in 10 mM Tris buffer pH 10.0 as described
previously [30]. Protein in the bile was assayed using a
kit from Bio-Rad using albumin as a standard.
Western blot for NPP7
Western blot was performed as described previously [23].
Normally 50 μg of the precipitated bile proteins were
subjected to 10% SDS-PAGE and transferred to a nitro-
cellulose membrane. The membrane was probed with
anti-NPP7 antibody (1:5000) obtained from R&D System
(Abingdon, UK). After washing, the membranes were re-
acted with second antibody against rabbit IgG conjugated
with horseradish peroxidase. The NPP7 bands were iden-
tified by ECL advance reagents and the remitted light was
recorded on Fuji Image. A standard purified NPP7 from
human bile was routinely loaded as a positive marker of
the product of 1.4 kb transcript. The densities of the
NPP7 bands and the ratio of the densities of the products
from 1.4 kb/1.2 kb transcripts were analyzed by MyImage
Analysis Software from Thermo Scientific.
Clinical biochemical analysis of the serum
Bilirubin, alkaline phosphatase and γ-glutamyltranspepti-
dase (γ-GT) in plasma were analysed the day before or in
the morning the same day as the ERCP were available in
58 patients and C-reactive protein taken at these times in
38 patients. The levels of bilirubin, ALP and γ-GT were
determined at the Clinical Chemistry Laboratory, Skåne
University Hospital, Lund Sweden on a Cobas 701 in-
strument using reagents from Roche (Roche Diagnostics,Mannheim, Germany). Reference values are 5–25 μmole/L
for bilirubin, 0.60–1.8 μkat/L for ALP and 0.15–1.2 μkat/L
for women and 1.2–1.9 μkat/L for men >40 years old.
Statistical analysis
Statistical analysis was performed by soft program Graph-
pad Prism 5. Since the groups in comparison were inde-
pendent of each other, and the values showed non-normal
distribution, the significance of the differences between
different groups were evaluated by Mann–Whitney test,
whereas the correlation was analysed by linear regression
test. P < 0.05 was considered to be statistically significant.
Results
Patients
Age and sex distribution in disease groups are shown in
Table 1. The gallstone group comprises 29 patients. Com-
mon bile duct stones (CBDS) were removed at ERCP in
22 patients with gallstone disease, after a sphincterotomy
had been performed. The remaining 7 patients all had a
history of gallstone disease and 5 of them had previously
undergone cholecystectomy. The clinical suspicion of
CBDS was strong, but at ERCP no stones or only sludge
was found. It was, however, considered likely that the
stones had passed recently.
In the tumour group of 13 patients, 5 had cholan-
giocarcinoma, 1 had gallbladder cancer, 5 had pancreatic
cancer, 1 had a hepatocellular carcinoma superimposed
on an advanced PSC, and 1 had colon cancer with liver
metastases.
The group designated “Others” consists of 7 patients,
of which 1 was severely icteric and appeared to have
severe alcohol related liver disease with cholestatic fea-
tures, and 1 had severe icterus and a cholestatic profile for
unknown reasons, combined with renal insufficiency. The
other 5 were less severely ill. They underwent ERCP be-
cause of abdominal pain, moderately pathologic liver tests
and in two cases widened common bile duct on ultrason-
ography. At ERCP 1 was considered to have a benign
stricture of the common bile duct, and 1 had an irregular
common bile duct for unknown reasons. Brush cytology
was normal and no sign of malignancy appeared during a
two year follow up.
NPP7 activity
The results of the NPP7 analyses and cholestatic plasma
parameters are shown in Table 2. Regardless if the NPP ac-
tivity was expressed per ml bile or per mg protein in bile,
the activity in the tumour group (T) was lower than in
gallstone group (G) (p < 0.05). NPP7 in bile from the com-
bined groups with gallstone and other (O) benign diseases
(G +O) was also significantly higher than in the T and T
plus primary sclerosing cholangitis (T + PSC) groups. Fur-
thermore the NPP7 in the combined (T + PSC) was lower
Table 2 NPP7 activity in the bile and the results of other clinical chemical analysis in patients in different groups
Group NPP7 nmol/h/ml NPP7 nmol/h/mg Bilirubin ALP GT n
Gallstone 311.6 ± 290.1 58.21 ± 69.93 54.59 ± 63.19 2.91 ± 1.60 6.69 ± 5.74 29
Tumor 164.9 ± 147.1* 25.16 ± 14.49* 161.2 ± 135.3** 12.2 ± 11.2** 14.15 ± 9.87* 13
PSC 184.4 ± 115.0 30.14 ± 26.97 56.67 ± 65.68 4.39 ± 3.00 5.06 ± 5.13 10
Others 312.6 ± 236.1 50.95 ± 31.09 124.9 ± 197.8 4.08 ± 3.52 4.75 ± 4.12 7
G + O 311.8 ± 277.3+ 56.89 ± 63.92+ 68.25 ± 103.4 3.14 ± 2.09 6.31 ± 5.47++ 36
T + PSC 173.2 ± 131.4* 27.33 ± 20.45* 118.5 ± 121.9* 9.19 ± 9.69** 10.44 ± 9.31 23
The results are expressed as Mean ± SD. Statistical significance was determined by non-paired, two tails Mann–Whitney test. *P < 0.05, **P < 0.01 or less compared with
gallstone group; + P < 0.05, ++ P < 0.01 or less, compared with tumor group. Significance was also found when gallstone + other benign diseases (G + O) was
compared with tumour + PSC (T + PSC) for NPP7 and ALP, either per ml or per mg.
80)g
m Tumor group
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enzyme activities per ml of bile and per mg bile protein
correlated strongly (Figure 1). The NPP7 activity in tu-
mour group is shown in Figure 2. Within this group, the
NPP7 activity in the five patients with cholangiocarcinoma
was significantly lower than in the five patients with pan-
creatic cancer (Figure 2). For comparison, the levels of
NPP7 activity in gallstone group are also shown in the
figure.
When NPP7 values were correlated to plasma biliru-
bin, ALP, and γ-GT in all patients, a weak inverse corre-
lation between bilirubin and NPP7 activity was identified
(P = 0.054) (Figure 3A). Within the gallstone group there
was a positive correlation between NPP7 activity and
plasma ALP, although plasma ALP was only modestly
raised in this group (Figure 3B). In the group of cholangio-
carcinoma in Figure 2 bilirubin was 243 ± 172 μmole/L
compared to 67 ± 40 μmole/L (p = 0.08) in the group of
pancreatic cancers. C-reactive protein did not correlate to
NPP7 activity (data not shown) and there was no indica-
tion that inclusion of some patients with pancreatitis orFigure 1 Correlation of NPP7 activities in bile expressed as per
ml and per mg sample protein. NPP7 activity was determined
using 14C-labeled sphingomyelin as substrate and the activities were
expressed as the cleaved phosphocholine per ml of the bile and per
mg of the bile proteins.cholangitis related to stone in ductus choledochus signifi-
cantly influenced group comparisons.
Two patients, a 73 year old woman with PSC and a
67 year old man with cholangiocarcinoma had extremely
low levels of NPP7, 1.2 and 0.1 nmole/h/mg protein re-
spectively. These patients had bilirubin levels of 22 and
156 μmole/L and ALP levels of 4.9 and 1.9 μkat/L
respectively. ALP values in bile varied considerably bet-
ween individuals but did not correlate to plasma biliru-
bin or γ-GT.
Western blot for NPP7 isoforms
To identify the occurrence of the inactive 1.2 kb product
of NPP7, all the bile samples available (55 of 59 samples)
were analysed by Western blotting. The antibody used
can well identify these two isoforms as shown in Figure 4,




































Figure 2 NPP7 activities in patients in the tumour group. The
bile NPP7 activity was determined as described. N = 5 for pancreatic
cancer and 5 for bile duct cancer (cholangiocarcinoma). N = 1 for
gallbladder cancer, colorectal cancer (CRC) and hepatocellular carcinoma
(HCC). The results are expressed as Mean of SE and ***P < 0.005
compared with Pancreas. For comparison, the values from gallstone













































Figure 3 Correlation of plasma bilirubin (A) and alkaline
phosphatase (B) with NPP7 activity. The plasma bilirubin and
alkaline phosphatase (ALP) were assayed just before ERCP and bile
NPP7 activity was assayed in the bile taken from ERCP. Correlation of
the NPP7 activity to the plasma bilirubin in all samples is shown in
panel A, and that of NPP7 activity to ALP in gallstone group is shown
in panel B.



































Figure 5 Correlation of the ratio of protein bands from 1.4 and
1.2 kb transcript to NPP7 activities in all samples. The densities
of the two protein bands identified by Western blot were determined
and the ratios of the two products in the same sample were analysed.
The correlation of the ratio with NPP7 activities in all samples was
determined.
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molecular masses corresponding to both the 1.4 kb and
the 1.2 kb mRNA form. The density of the two bands
were then determined and the density ratios of the iso-
forms for each bile sample were calculated. As shown in
Figure 5 the ratio correlated significantly to the NPP7





Figure 4 A representative figure of Western blot showing the
identification of the two isoforms. The proteins in the bile were
precipitated and 50 μg of proteins of each samples were subject to
Western blot. Lane 0: standard proteins. Lane 1: purified human bile
NPP7. Lane 2 to 7: samples from patients. As shown, two isoforms
could be identified.above with extremely low levels of NPP7 activity showed
no band of the 1.4 kb product by Western blot.
Discussion
The present study for the first time examines the activity
and isoforms of NPP7 in the bile in humans with dif-
ferent diseases. The major findings are that although
almost all bile samples contained considerable NPP7 ac-
tivity, the activities were significantly decreased in the
bile of patients with cholangiocarcinoma.
NPP7 is expressed in the intestinal tract and additionally
in human liver [11]. NPP7 from human liver is released in
bile, probably by bile salt action on the canalicular mem-
brane, analogous to the release from intestinal segments
by luminal bile salt perfusion [4]. Due to the generation of
ceramide and inactivation of PAF, the enzyme has been
considered to have anticancer properties [11]. Reduction
of NPP7 level has been reported in colorectal cancer [19]
and longstanding colitis [20], and an inactive isoform of
NPP7 was identified in both colon cancer HT29 and liver
cancer Hep G2 cell lines [15,25]. In the present study, the
lowered NPP7 activity in bile of patients with cancers
comparing with those with gallstones is in agreement with
previous studies in human colon cancer samples [19]. The
finding that most obvious reduction of NPP7 was found
in cholangiocarcinoma patients is of particular interest.
Cholangiocarcinoma is a cancer with increasing incidence,
and the disease is considered incurable except for the few
cases where surgical removal is possible. Due to the lack
of an early marker, most cholangiocarcinomas are diag-
nosed at a stage when surgical cure is impossible, and the
5 year survival rate for the patients is almost zero [31,32].
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can be a marker in prediction of cholangiocarcinoma at
early stage is attractive. It may be noteworthy that re-
duced NPP7 activity was also found in the patients with
the chronic bile duct inflammation PSC, which has
strong links to ulcerative colitis and risk for cholangio-
carcinoma [33,34].
The occurrence of the aberrant NPP7 from the 1.2 kb
mRNA in the majority of the bile samples is not a fin-
ding we expected, but interesting. It may indicate that
appearance of the aberrant isoform cannot simply be
used as a marker for malign hepatobiliary disease. The
strong correlation between the ratio of 1.4/1.2 kb pro-
ducts and NPP7 activity supports our previous finding
that the 1.4 kb product is active whereas the 1.2 kb form
is not [25]. It also suggests that the secretion of the
1.2 kb product in bile was actually less affected than the
secretion of the 1.4 kb product in the tumour and
tumour plus PSC group. The result also argues against a
nonspecific effect of cholestasis as explanation of the
lower NPP7 activity in these groups. Interestingly two
patients, a 73 year old woman with PSC and a 68 year
old man with cholangiocarcinoma (Klatskin tumour)
had almost immeasurable NPP7 activity but strong
bands corresponding to the 1.2 kb and no band mat-
ching the 1.4 kb transcript. Although the aberrant 1.2 kb
form has no activity against SM, this protein may have
other functions that have not been identified. It is well
known that alternative splicing is an important me-
chanism to produce isoforms with different, or opposite
functions compared to the normal product [35,36].
NPP7 has 5N-glycosylation sites and defect glycosyla-
tion reduces the enzyme activity [37]. Since the identifica-
tion of the 1.4 and 1.2 kb products in the present study
was based on Western blot, one might ask whether the
product with smaller molecular weight is derived from
abnormally glycosylation. We consider this an unlikely ex-
planation of the molecular mass difference. The 1.2 kb
mRNA for the isoform has been shown to be expressed in
liver cells and transfection of Cos7 cells with the 1.2 kb
cDNA produces a protein band on Western blot similar as
the one found in this study [15]. In addition, Dr. Yang LP
in Nantong Cancer Research Institute, Jiangsu Province,
China, also found the two bands on Western blot in hu-
man colon cancer tissues. In their experiment, pretreating
colon cancer samples with glycosidase did not affect the
size differences between the two bands on Western blot
(personal communication). However, further studies to
characterize sugar moiety of the two products in human
bile is still necessary, as abnormal glycosylation has great
impact on carcinogenesis [38].
In the present study, we also found a week positive
correlation between bile NPP7 and plasma ALP within
the gallstone group, suggesting that cholestatic stressmay increase NPP7 secretion in bile. There was, how-
ever, no such correlation in whole patient population or
within the tumour group which had higher ALP level
than the gallstone patients. In the whole patient popula-
tion there was rather a week inverse correlation between
NPP7 and bilirubin levels, and NPP7 was lower but bili-
rubin higher in cholangiocarcinoma than in pancreas
cancer patients. If cholestasis itself stimulates secretion
of NPP7 into bile, other factors thus may act in tumour
group to counteract this phenomenon. Although we
earlier found a trend towards low NPP7 levels in liver
biopsies from humans with liver disease [15], only one
of the tumour patients in this study had known liver dis-
ease (hepatocellular cancer in a PSC liver). Pre-existing
liver disease therefore does not explain the lower NPP7
values in the tumour group.
Conclusions
In conclusion NPP activity was decreased with malign
hepatobiliary diseases and lowest activity was associated
with cholangiocarcinoma. Although the occurrence of
both the normal 1.4 kb and the aberrant inactive 1.2 kb
form of NPP7 in human bile is a general phenomenon,
the NPP7 activity is derived from the 1.4 kb form. How-
ever, what determines the partitioning between the two
forms, and the identity and function of the 1.2 kb form
require further study.
Limitations of the study
Although the results of the study are potentially impor-
tant, a few limitations need to be noted. Since cholangio-
carcinoma is not a common cancer disease, the number of
the patients with cholangiocarcinoma in the present study
is small. Further study in a large scale is required. In
addition, as an ectoenzyme, bile NPP7 is expected to be
expressed in the canalicular membrane of the hepatic
cells, but the precise location of NPP7 in liver cells has
not been clearly demonstrated. This is partly due to the
fact that NPP7 has not been found in the liver of animals
so far, and its levels are down regulated in cancer tissues.
Immunohistochemistry study on normal and diseased hu-
man liver should be performed when possible. Finally we
also lack the genetic analysis on the two patients in the
study who lack NPP7.
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